[{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Bayer AG"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-ADC","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-MAB","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Translational Research In Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Translational Research In Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Effector Therapeutics | Stand Up To Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"MAP kinase-interacting serine\/threonine-protein kinase 1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Translational Research In Oncology \/ Effector Therapeutics | Stand Up To Cancer","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Effector Therapeutics | Stand Up To Cancer"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase III","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Translational Research In Oncology \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Translational Research In Oncology \/ Bayer AG"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Bayer AG | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Bayer AG | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Bayer AG | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-3-600","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"TORL BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-4-500","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"UCT-03-008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"}]
Find Clinical Drug Pipeline Developments & Deals by Translational Research In Oncology
Details :
Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.
Details :
Regorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anus Neoplasms.
Details :
Kisqali (ribociclib) is a unique CDK4/6 inhibitor, consistently demonstrating statistically significant OS benefit while maintaining or improving quality of life across three Phase III trials, regardless of patient or disease characteristics.
Details :
TORL-1-23 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Details :
Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging anti-tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer pati...
Reset All
